Ultimovacs
ISIN: NO0010851603 | Ticker: ULTI | LEI: 254900B4VALJZR9TL744
Country: Norway
Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.
Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.
2011
Served areaWorldwide
HeadquartersUllernchausséen 64, 0253 Oslo – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 529,717,000.00 | 655,537,000.00 | 509,672,000.00 |
| Noncurrent Assets | N/A | 80,354,000.00 | 73,282,000.00 | 74,093,000.00 |
| Property Plant And Equipment | N/A | 377,000.00 | 212,000.00 | 220,000.00 |
| Goodwill | N/A | 11,795,000.00 | 11,031,000.00 | 10,701,000.00 |
| Current Assets | N/A | 449,363,000.00 | 582,255,000.00 | 435,579,000.00 |
| Trade And Other Current Receivables | N/A | 8,438,000.00 | 8,087,000.00 | 10,270,000.00 |
| Cash and cash equivalents | 399,607,000.00 | 440,925,000.00 | 574,168,000.00 | 425,309,000.00 |
| Equity And Liabilities | N/A | 529,717,000.00 | 655,537,000.00 | 509,672,000.00 |
| Equity | 444,633,000.00 | 488,380,000.00 | 593,152,000.00 | 449,350,000.00 |
| Issued Capital | N/A | 3,197,000.00 | 3,422,000.00 | 3,440,000.00 |
| Retained Earnings | N/A | -339,599,000.00 | -504,321,000.00 | -672,113,000.00 |
| Share Premium | N/A | 809,214,000.00 | 1,070,841,000.00 | 1,076,308,000.00 |
| Other Reserves | N/A | 8,762,000.00 | 20,358,000.00 | 40,752,000.00 |
| Liabilities | N/A | 41,337,000.00 | 62,384,000.00 | 60,321,000.00 |
| Noncurrent Liabilities | N/A | 13,870,000.00 | 11,488,000.00 | 14,414,000.00 |
| Deferred Tax Liabilities | N/A | 11,795,000.00 | 11,031,000.00 | 10,701,000.00 |
| Current Liabilities | N/A | 27,467,000.00 | 50,897,000.00 | 45,907,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 8,611,000.00 | 22,555,000.00 | 7,655,000.00 |
| Other Current Liabilities | N/A | 17,149,000.00 | 26,714,000.00 | 36,485,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Employee Benefits Expense | 50,989,000.00 | 61,916,000.00 | 71,466,000.00 |
| Depreciation And Amortisation Expense | 2,720,000.00 | 2,703,000.00 | 2,648,000.00 |
| Other Expense By Nature | 70,438,000.00 | 99,213,000.00 | 109,517,000.00 |
| Profit Loss From Operating Activities | -124,146,000.00 | -163,832,000.00 | -183,631,000.00 |
| Finance Income | 5,209,000.00 | 13,383,000.00 | 17,375,000.00 |
| Finance Costs | 1,616,000.00 | 14,272,000.00 | 1,536,000.00 |
| Profit Loss Before Tax | -120,552,000.00 | -164,722,000.00 | -167,792,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -120,552,000.00 | -164,722,000.00 | -167,792,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -120,552,000.00 | -164,722,000.00 | -167,792,000.00 |
| Adjustments For Finance Costs | N/A | 236,000.00 | 179,000.00 | N/A |
| Adjustments For Depreciation And Amortisation Expense | N/A | 2,720,000.00 | 2,703,000.00 | 2,648,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 747,000.00 | 3,619,000.00 | -7,176,000.00 |
| Adjustments For Sharebased Payments | N/A | 6,777,000.00 | 11,595,000.00 | 20,395,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -108,223,000.00 | -125,828,000.00 | -167,695,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 282,000.00 | 85,000.00 | 195,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 5,000,000.00 | 0.00 | 0.00 |
| Interest Received Classified As Investing Activities | N/A | 4,545,000.00 | 3,062,000.00 | 8,887,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -736,000.00 | 2,977,000.00 | 8,691,000.00 |
| Proceeds From Issuing Shares | N/A | 160,000,000.00 | 272,864,000.00 | 5,484,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,680,000.00 | 1,716,000.00 | 1,802,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 236,000.00 | 179,000.00 | 105,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 151,017,000.00 | 259,957,000.00 | 3,577,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 42,058,000.00 | 137,106,000.00 | -155,426,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -739,000.00 | -3,863,000.00 | 6,567,000.00 |
| Cash and cash equivalents | 399,607,000.00 | 440,925,000.00 | 574,168,000.00 | 425,309,000.00 |
Please note that some sums might not add up.
NO0010851603
LEI254900B4VALJZR9TL744
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.